Please provide your email address to receive an email when new articles are posted on . Cardiovascular risk-screening and stratification is advised for IBD patients before JAK inhibitor or S1P ...

Oral small-molecule therapies are redefining first-line treatment in moderate to severe ulcerative colitis (UC) by offering noninfusion alternatives with rapid onset and high efficacy. Etrasimod, a ...

Connect Biopharma Holdings Ltd. pointed to positive secondary endpoint data and a numerical trend on the primary endpoint in favor of its S1P receptor modulator, CBP-307, in ulcerative colitis, but ...

The study did not meet its primary endpoint of clinical remission at week 12. A phase 3 trial evaluating ozanimod, a sphingosine 1-phosphate (S1P) receptor modulator, in patients with moderate to ...

MS treatments during pregnancy do not seem to increase the risk of neurodevelopmental disorders in exposed children, a study ...